• HOME
  • GET INVOLVED
  • RESEARCH SITES
  • CURRENT RESEARCH
    • Research Finder
  • NEWS
  • RESOURCES
    • STAFF ONLY
    • Mechanistic Scientific Core
    • FOR RESEARCHERS
  • ABOUT US
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / Current Research2 / ITAD

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

Recruitment closed
30/09/2021

Summary 

ITAD is a multicentre, randomised, double-blind, placebo-controlled clinical trial of  to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes.

We know that the longer people with diabetes can produce their own insulin, the better it is for the control of their blood glucose levels and long-term complications.

At diagnosis, there are usually a small number of beta cells (10-20%) left in the pancreas, which still produce small amounts of insulin.  We call this ‘beta cell function’ and we assess this by measuring C-peptide, which is made by the pancreas when insulin is produced.  Most people with type 1 diabetes eventually stop producing insulin themselves, this may occur rapidly in a few months, or more slowly over several years.

New treatments preserving insulin production could improve management of diabetes. This could be done by using drugs acting on cells of the immune system.  In type 1 diabetes, there is an imbalance between cells of the immune system, and there is evidence that one protein produced by our body, called Interleukin-2, could help in resetting the balance between those cells. It is important to start this treatment soon after diagnosis because this is when there is the best chance of saving the beta cells still left in the pancreas.

45 participants aged 6 to 18 will be recruited within 6 weeks of diagnosis of Type 1 Diabetes from a minimum of 6 UK sites and will be randomised 2:1 to either aldesleukin or placebo, as subcutaneous injection, twice a week for 6 months.  Participants will then be followed up for a further 6 months. Participants will have 7 study visits during their 12 months on the study.

Eligibility to take part

  1. Can give informed consent
  2. Aged 6 – 18 years
  3. Diagnosed with T1D (at least one autoantibody positive), requiring insulin treatment
  4. Within 6 weeks from diagnosis
  5. Have random C-peptide > 200 pmol/l
  6. Normal full blood count

If you are interested in taking part, please click the “Get Involved” button below:

Get Involved

Site Locator

      • ARAD – At Risk of Autoimmune Diabetes
      • Barricade-delay
      • Beta Preserve
      • CFZ533X2207 Trial
        • CFZ533X2207 Trials Map
      • ELSA – Early Surveillance for Autoimmune diabetes
      • EXTOD Immune
      • Fabulinus
      • IMPACT Study
        • IMPACT Trials Map
      • INNODIA – People at Increased Risk
      • MELD-ATG Trial
        • MELD-ATG Trials Map
      • PROTECT Study
        • PROTECT Trials Map
      • Safeguard
      • SMART
      • STRIDE
      • T1D-Plus
      • Type 1 Diabetes Risk in Adults
      • UK Islet Autoantibody Registry
      • Ver-A-T1D Trial
        • Ver-A-T1D Trials Map
      • USTEKID
        • USTEKID Staff Only
        • USTEKID Trials Map
      • ITAD
        • ITAD Staff Only
        • ITAD Trials Map
      • Research study for people with Type 1 Diabetes: EXALT
      • The Effect of Abatacept on the Immune System in Type 1 Diabetes
      • The Effect of Anti-IL-21 and Liraglutide in Newly Diagnosed Type 1 Diabetes

      UKT1D logo

      Moving towards insulin-free T1D

      SITEMAP

      • HOME
      • GET INVOLVED
      • RESEARCH SITES
      • CURRENT RESEARCH
        • Research Finder
      • NEWS
      • RESOURCES
        • STAFF ONLY
        • Mechanistic Scientific Core
        • FOR RESEARCHERS
      • ABOUT US

      storyset attribution

      Business illustrations by Storyset
      © Copyright - T1DUK
      • Link to X
      • Link to Youtube
      • Privacy Policy
      Scroll to top Scroll to top Scroll to top

      This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

      OKLearn more

      Cookie and Privacy Settings



      How we use cookies

      We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

      Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

      Essential Website Cookies

      These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

      Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

      We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

      We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

      Google Analytics Cookies

      These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

      If you do not want that we track your visit to our site you can disable tracking in your browser here:

      Other external services

      We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

      Google Webfont Settings:

      Google Map Settings:

      Google reCaptcha Settings:

      Vimeo and Youtube video embeds:

      Other cookies

      The following cookies are also needed - You can choose if you want to allow them:

      Privacy Policy

      You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

      Privacy Policy
      Accept settingsHide notification only